A Phase I, open-label, dose-escalation study of BI 765063 with or without ezabenlimab in patients with advanced solid tumors (NCT03990233)
AE, adverse event; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; MTD, maximum tolerated dose; ORR, objective response rate; PK, pharmacokinetics; SIRPα, signal-regulatory protein alpha.